KR102513124B1 - Composition for improving environment of scalp, relieving odor of scalp and suppressing danddruff - Google Patents
Composition for improving environment of scalp, relieving odor of scalp and suppressing danddruff Download PDFInfo
- Publication number
- KR102513124B1 KR102513124B1 KR1020220066770A KR20220066770A KR102513124B1 KR 102513124 B1 KR102513124 B1 KR 102513124B1 KR 1020220066770 A KR1020220066770 A KR 1020220066770A KR 20220066770 A KR20220066770 A KR 20220066770A KR 102513124 B1 KR102513124 B1 KR 102513124B1
- Authority
- KR
- South Korea
- Prior art keywords
- scalp
- weight
- parts
- composition
- improving
- Prior art date
Links
- 210000004761 scalp Anatomy 0.000 title claims abstract description 119
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 208000001840 Dandruff Diseases 0.000 claims abstract description 27
- 230000036541 health Effects 0.000 claims abstract description 26
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000001939 cymbopogon martini roxb. stapf. oil Substances 0.000 claims abstract description 22
- 210000002374 sebum Anatomy 0.000 claims abstract description 16
- 208000003251 Pruritus Diseases 0.000 claims abstract description 14
- 241000894006 Bacteria Species 0.000 claims abstract description 12
- 230000007803 itching Effects 0.000 claims abstract description 12
- 239000001384 succinic acid Substances 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 230000028327 secretion Effects 0.000 claims abstract description 9
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940081510 piroctone olamine Drugs 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 claims abstract description 5
- 230000035755 proliferation Effects 0.000 claims abstract description 5
- 229940116411 terpineol Drugs 0.000 claims abstract description 5
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 claims abstract 2
- 229930003658 monoterpene Natural products 0.000 claims description 13
- 150000002773 monoterpene derivatives Chemical class 0.000 claims description 13
- 235000002577 monoterpenes Nutrition 0.000 claims description 13
- 239000002537 cosmetic Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- -1 pyroctonolamine Substances 0.000 claims description 7
- 230000007794 irritation Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 claims description 4
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 claims description 4
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 claims description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 2
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 claims description 2
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 claims description 2
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 claims description 2
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 claims description 2
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 claims description 2
- 229930006739 camphene Natural products 0.000 claims description 2
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 claims description 2
- 229960005233 cineole Drugs 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 229940041616 menthol Drugs 0.000 claims description 2
- 150000007823 ocimene derivatives Chemical class 0.000 claims description 2
- XJPBRODHZKDRCB-UHFFFAOYSA-N trans-alpha-ocimene Natural products CC(=C)CCC=C(C)C=C XJPBRODHZKDRCB-UHFFFAOYSA-N 0.000 claims description 2
- 229930007845 β-thujaplicin Natural products 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 3
- 206010000496 acne Diseases 0.000 abstract description 3
- 230000005808 skin problem Effects 0.000 abstract 1
- 238000005259 measurement Methods 0.000 description 18
- 238000011156 evaluation Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 5
- 201000004384 Alopecia Diseases 0.000 description 5
- 102000011782 Keratins Human genes 0.000 description 5
- 108010076876 Keratins Proteins 0.000 description 5
- 241000555688 Malassezia furfur Species 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 208000024963 hair loss Diseases 0.000 description 5
- 230000003676 hair loss Effects 0.000 description 5
- 206010039897 Sedation Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 230000036280 sedation Effects 0.000 description 4
- 239000002453 shampoo Substances 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000004332 deodorization Methods 0.000 description 2
- 230000001877 deodorizing effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013538 functional additive Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000003646 hair health Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- WRYLYDPHFGVWKC-SNVBAGLBSA-N 4-Terpineol Natural products CC(C)[C@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-SNVBAGLBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101001001645 Homo sapiens Serine/threonine-protein kinase pim-3 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 102100036119 Serine/threonine-protein kinase pim-3 Human genes 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/008—Preparations for oily hair
Abstract
Description
본 발명은 팔마로사 오일, 피록톤올아민, 및 숙신산 및 테르피네올 중 하나 이상을 유효성분으로 포함하는, 두피 건강 개선용 조성물에 관한 것이다.The present invention relates to a composition for improving scalp health, comprising palmarosa oil, pyroctonolamine, and at least one of succinic acid and terpineol as active ingredients.
또한, 본 발명은 팔마로사 오일, 피록톤올아민, 및 숙신산 및 테르피네올 중 하나 이상을 유효성분으로 포함하는, 두피 환경 개선, 두피 냄새 완화 및 비듬 억제용 조성물에 관한 것이다.In addition, the present invention relates to a composition for improving the scalp environment, mitigating scalp odor, and inhibiting dandruff, comprising palmarosa oil, pyroctonolamine, and at least one of succinic acid and terpineol as active ingredients.
두피(SCALP)는 두개골의 체표를 덮고 있는 피부조직으로, 모발이 생장하는 신체 부위이다. 모발은 자외선 등의 외부 자극요인으로부터 두피를 보호하고, 머리의 온도를 일정하게 유지하는 기능을 담당할 뿐만 아니라, 사람의 외관적 미(美)를 결정짓는데 큰 영향을 미친다. 이에, 외모에 대한 대중의 관심이 높아진 현대사회에서, 일반인들은 두피와 모발의 건강에 대하여 큰 관심을 보이고 있다.The scalp (SCALP) is a skin tissue covering the body surface of the skull, and is a body part where hair grows. Hair not only protects the scalp from external stimulants such as ultraviolet rays and maintains a constant temperature of the hair, but also has a great influence on determining the external beauty of a person. Accordingly, in modern society where the public's interest in appearance has increased, the general public is showing great interest in the health of the scalp and hair.
한편, 현대 사회에 들어서면서 과도한 스타일링제의 사용, 잦은 펌 및 염색, 미세먼지를 포함한 환경오염 등의 다양한 원인으로 인해 두피 및 모발 건강의 악화로 고통을 호소하는 일반인들이 증가하고 있다.On the other hand, as we enter modern society, more and more people are complaining of suffering from deterioration in scalp and hair health due to various causes such as excessive use of styling agents, frequent perm and dyeing, and environmental pollution including fine dust.
두피 및 모발 건강 악화는 일반적으로, 건성 두피, 지성 두피, 민감성 두피, 두피염, 비듬 및 탈모 등의 증세로 발현된다. 건성 두피는 유·수분 밸런스가 맞지 않아 두피 및 모발이 매우 건조하며 푸석푸석하여 윤기가 없다. 또한, 두피의 혈액순환이 원활하지 못하여 각질이상으로 비듬이 쌓이고 탈모가 유발될 수도 있다. 지성 두피는 두피상의 피지 분비가 과도하여 비듬과 각질이 피지와 엉켜있는 상태의 두피를 의미하며, 피지 분비물이 모공을 막고 있어 염증을 유발하거나 모발의 성장을 방해하여 탈모의 원인이 되기도 한다. 민감성 두피는 예민성 두피라고도 불리며, 모세혈관이 과도하게 확장되어 있어 외부로부터 약한 자극에도 민감하게 반응하고 염증 반응이 폭발적으로 발생한다. 비듬이란 비듬균의 이상증식으로 두피에 각질이 쌓이는 것을 의미하며, 건성 비듬과 지성 비듬으로 구분된다. 탈모는 모발의 주기가 수명을 다하지 못하고 모발이 빠지는 현상을 의미한다. Scalp and hair health deterioration is generally expressed as symptoms such as dry scalp, oily scalp, sensitive scalp, scalp inflammation, dandruff and hair loss. In a dry scalp, the oil/moisture balance is not right, so the scalp and hair are very dry, crumbly, and lacking in luster. In addition, the blood circulation of the scalp is not smooth, so dandruff is accumulated due to dead skin cells and hair loss may be induced. Oily scalp refers to the scalp in a state where dandruff and dead skin cells are entangled with sebum due to excessive secretion of sebum on the scalp, and sebum secretion clogs pores, causing inflammation or hindering hair growth, causing hair loss. Sensitive scalp is also called sensitive scalp, and capillaries are excessively dilated, so it reacts sensitively even to weak stimuli from the outside and an inflammatory reaction occurs explosively. Dandruff refers to the accumulation of dead skin cells on the scalp due to the abnormal proliferation of dandruff bacteria, and is divided into dry dandruff and oily dandruff. Hair loss refers to a phenomenon in which the cycle of hair does not reach its end of life and the hair falls out.
한편, 두피의 모공은 다른 부위의 피부 상에 존재하는 모공과 비교하여 그 직경이 크고, 다른 피부와 달리 모발로 덮여 있는 등 노폐물이 잘 쌓일 수 있는 구조를 가지고 있고, 두피는 다른 부위의 피부와 비교하여 피지선이 많아, 미생물 증식에 유리한 환경이다. 따라서, 두피 내 유수분 밸런스가 무지는 등의 이유로 두피 건강이 악화되면, 건강한 상태의 두피로 회복시키는 것이 어려운 것으로 알려져 있다. 이에, 지난 수년간 매우 다양한 헤어 용품들이 개발되고 있으나, 아직까지 뚜렷한 효과를 보인 제품은 보고된 바 없다.On the other hand, the pores of the scalp have a larger diameter than the pores existing on the skin of other parts, and unlike other skin, they have a structure in which waste materials can be accumulated well, such as being covered with hair, and the scalp is different from the skin of other parts. In comparison, there are many sebaceous glands, which is a favorable environment for the growth of microorganisms. Therefore, it is known that it is difficult to restore the scalp to a healthy state when the health of the scalp deteriorates due to an ignorance of the oil-moisture balance in the scalp. Accordingly, a wide variety of hair products have been developed over the past few years, but no product with a clear effect has been reported yet.
일 측면에서, 본 발명의 목적은 두피 건강을 개선하는 것이다.In one aspect, an object of the present invention is to improve scalp health.
일 측면에서, 본 발명의 목적은 두피의 환경을 개선하는 것이다.In one aspect, an object of the present invention is to improve the environment of the scalp.
일 측면에서, 본 발명의 목적은 두피, 특히 정수리에서의 악취 발생을 억제하고, 발생한 악취를 제거 또는 완화하는 것이다.In one aspect, an object of the present invention is to suppress the occurrence of malodor in the scalp, particularly the crown, and to remove or mitigate the generated malodor.
일 측면에서, 본 발명의 목적은 두피상의 여드름, 트러블, 염증 및 가려움을 개선하는 것이다.In one aspect, an object of the present invention is to improve acne, trouble, inflammation and itching on the scalp.
일 측면에서, 본 발명의 목적은 두피상의 피지 분비량을 적절히 조절하는 것이다.In one aspect, an object of the present invention is to appropriately control the amount of sebum secretion on the scalp.
일 측면에서, 본 발명의 목적은 비듬균의 증식과 비듬 생성을 억제하는 것이다.In one aspect, an object of the present invention is to inhibit the growth of dandruff bacteria and the production of dandruff.
일 측면에서, 본 발명의 목적은 모발이 건강하게 생장할 수 있는 두피 환경을 제공하는 것이다.In one aspect, an object of the present invention is to provide a scalp environment in which hair can grow healthily.
일 측면에서, 본 발명의 목적은 두피 건강 저하로 인한 모발의 탈락을 개선 및 예방하는 것이다.In one aspect, an object of the present invention is to improve and prevent hair loss due to deterioration of scalp health.
상기와 같은 목적을 달성하기 위해, 본 발명은 팔마로사 오일(Palmarosa oil) 및 피록톤올아민(Piroctone Olamine)을 유효성분으로 포함하며, 상기 피록톤올아민은, 팔마로사 오일 100 중량부를 기준으로, 10-4 중량부 내지 200 중량부로 포함되는, 두피 건강 개선용 조성물 조성물을 제공한다.In order to achieve the above object, the present invention includes Palmarosa oil and Piroctone Olamine as active ingredients, and the Piroctone Olamine is based on 100 parts by weight of Palmarosa oil, 10 -4 It provides a composition for improving scalp health, which is included in parts by weight to 200 parts by weight.
본 발명의 일 측면에 따른 두피 건강 개선용 조성물은 두피의 피지 분비량을 적절히 조절하고, 비듬균 증식 및 생장을 억제하는 등 두피 건강을 근본적으로 개선할 수 있다. 따라서, 본 발명에 따른 두피 건강 개선용 조성물은 두피에서의 악취 제어, 두피 자극·여드름·트러블·염증·가려움증 개선 및 비듬 개선 효과를 기대할 수 있다. The composition for improving scalp health according to one aspect of the present invention can fundamentally improve scalp health, such as appropriately controlling the amount of sebum secretion of the scalp and inhibiting the proliferation and growth of dandruff bacteria. Therefore, the composition for improving scalp health according to the present invention can be expected to control odor from the scalp, improve scalp stimulation/acne/trouble/inflammation/itching, and reduce dandruff.
도 1은 본 발명의 일 측면에 따른 헤어 조성물을 처리한 후의 두피 진정 효과를 확인한 실험 결과이다(좌:사용 전, 우: 사용 2주 후).
도 2는 본 발명의 일 측면에 따른 헤어 조성물을 처리한 후의 두피 혈행 개선 효과를 확인한 실험 결과이다(좌:사용 전, 우: 사용 2주 후).1 is an experimental result confirming the scalp soothing effect after treating a hair composition according to an aspect of the present invention (left: before use, right: 2 weeks after use).
2 is an experimental result confirming the scalp blood circulation improvement effect after treatment with the hair composition according to one aspect of the present invention (left: before use, right: 2 weeks after use).
이하에서, 각 구성을 보다 상세히 설명하나, 이는 하나의 예시에 불과할 뿐, 본 발명의 권리범위가 다음 내용에 의해 제한되지 아니한다.Hereinafter, each configuration will be described in more detail, but this is only one example, and the scope of the present invention is not limited by the following content.
본 발명의 명세서 및 청구범위에 사용된 용어 또는 단어는 통상적이거나 사전적인 의미로 한정 해석되지 아니하며, 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다.Terms or words used in the specification and claims of the present invention are not limited to the usual or dictionary meaning, and the inventor can properly define the concept of the term in order to explain his/her invention in the best way. Based on the principle, it should be interpreted as a meaning and concept consistent with the technical idea of the present invention.
본 발명은 일 측면에서, 팔마로사 오일(Palmarosa oil) 및 피록톤올아민(Piroctone Olamine)을 유효성분으로 포함하며, 상기 피록톤올아민은, 팔마로사 오일 100 중량부를 기준으로, 10-4~200 중량부로 포함되는, 두피 건강 개선용 조성물이다.In one aspect, the present invention includes Palmarosa oil and Piroctone Olamine as active ingredients, and the Piroctone Olamine is included in an amount of 10 -4 to 200 parts by weight based on 100 parts by weight of Palmarosa oil. It is a composition for improving scalp health.
또한, 일 측면에서 본 발명은 팔마로사 오일(Palmarosa oil) 및 피록톤올아민(Piroctone Olamine)을 유효성분으로 포함하며, 상기 피록톤올아민은, 팔마로사 오일 100 중량부를 기준으로, 10-4~200 중량부로 포함되는, 두피 환경 개선용 조성물이다.In addition, in one aspect, the present invention includes Palmarosa oil and Piroctone Olamine as active ingredients, and the Piroctone Olamine is based on 100 parts by weight of Palmarosa oil, in an amount of 10 -4 to 200 parts by weight. It is a composition for improving the scalp environment, which is included.
본 명세서에서 '두피 환경'이란, 두피 및 모발의 건강에 직간접적으로 영향을 미치는 두피의 조건 또는 상태를 의미할 수 있다.In the present specification, 'scalp environment' may mean a condition or condition of the scalp that directly or indirectly affects the health of the scalp and hair.
일 측면에서, 상기 조성물은 피록톤올아민을, 팔마로사 오일 100 중량부를 기준으로 10-3 중량부 내지 200 중량부로 포함할 수 있고, 또는 10-2 중량부 내지 200 중량부, 또는 10-1 중량부 내지 200 중량부, 또는 1 중량부 내지 200 중량부, 또는 10 중량부 내지 200 중량부, 또는 30 중량부 내지 200 중량부, 또는 50 중량부 내지 200 중량부, 또는 70 중량부 내지 200 중량부, 또는 90 중량부 내지 200 중량부, 또는 110 중량부 내지 200 중량부, 또는 110 중량부 내지 180 중량부, 또는 120 중량부 내지 180 중량부, 또는 120 중량부 내지 170 중량부, 또는 130 중량부 내지 180 중량부, 또는 130 중량부 내지 170 중량부, 또는 140 중량부 내지 160 중량부로 포함할 수 있으나, 이에 제한되는 것은 아니다.In one aspect, the composition may include 10 -3 parts by weight to 200 parts by weight of pyroctoneolamine, based on 100 parts by weight of Palmarosa oil, or 10 -2 parts by weight to 200 parts by weight, or 10 -1 parts by weight. to 200 parts by weight, or 1 to 200 parts by weight, or 10 parts by weight to 200 parts by weight, or 30 parts by weight to 200 parts by weight, or 50 parts by weight to 200 parts by weight, or 70 parts by weight to 200 parts by weight, or 90 parts to 200 parts, or 110 parts to 200 parts, or 110 parts to 180 parts, or 120 parts to 180 parts, or 120 parts to 170 parts, or 130 parts by weight 180 parts by weight, or 130 parts by weight to 170 parts by weight, or 140 parts by weight to 160 parts by weight may be included, but is not limited thereto.
피록톤올아민과 팔마로사 오일이 상기와 같은 비율로 포함될 때, 더 우수한 두피 개선 효과와 두피 환경 개선 효과를 나타낼 수 있다.When piroctonolamine and palmarosa oil are included in the above ratio, a better scalp improvement effect and scalp environment improvement effect can be exhibited.
일 측면에서, 상기 조성물은, 숙신산(Succinic acid) 및 모노테르펜류(Monoterpenes) 중 하나 이상을 더 포함할 수 있다.In one aspect, the composition may further include at least one of succinic acid and monoterpenes.
일 측면에서, 상기 조성물이 숙신산 및 모노테르펜류 중 하나 이상을 더 포함할 경우, 더욱 향상된 두피 건강 또는 환경 개선 효과를 나타낼 수 있다.In one aspect, when the composition further includes at least one of succinic acid and monoterpenes, a more improved scalp health or environmental improvement effect may be exhibited.
또한, 일 측면에서, 상기 숙신산 및 모노테르펜류는, 팔마로사 오일 100 중량부를 기준으로, 각각 순서대로, 10-4 중량부 초과 내지 3000 중량부 및 10-4 중량부 초과 내지 200 중량부로 포함될 수 있다.In addition, in one aspect, the succinic acid and monoterpenes are based on 100 parts by weight of palmarosa oil, respectively, in order, greater than 10 -4 parts by weight to 3000 parts by weight and greater than 10 -4 parts by weight to 200 parts by weight. .
구체적으로, 상기 숙신산은 팔마로사 오일 100 중량부를 기준으로, 10-4 중량부 초과 내지 3500 중량부 미만으로 포함될 수 있고, 또는, 10-3 중량부 내지 3500 중량부 미만, 또는 10-2 중량부 내지 3500 중량부 미만, 또는 10-1 중량부 내지 3500 중량부 미만, 또는 1 중량부 내지 3500 중량부 미만, 또는 10 중량부 내지 3500 중량부 미만, 또는 100 중량부 내지 3500 중량부 미만, 또는 1000 중량부 내지 3500 중량부 미만, 또는 2000 중량부 내지 3500 중량부 미만, 또는 2500 중량부 내지 3500 중량부 미만, 또는 2800 중량부 내지 3300 중량부, 또는 2800 중량부 내지 3200 중량부, 또는 2900 중량부 내지 3100 중량부로 포함될 수 있으나, 이에 제한되는 것은 아니다.Specifically, the succinic acid may be included in an amount of more than 10 -4 parts by weight to less than 3500 parts by weight, or 10 -3 parts by weight to less than 3500 parts by weight, or 10 -2 parts by weight to less than 3500 parts by weight, based on 100 parts by weight of Palmarosa oil. less than 3500 parts by weight, or 10 -1 parts by weight to less than 3500 parts by weight, or 1 parts by weight to less than 3500 parts by weight, or 10 parts by weight to less than 3500 parts by weight, or 100 parts by weight to less than 3500 parts by weight, or 1000 parts by weight part to less than 3500 parts by weight, or 2000 parts by weight to less than 3500 parts by weight, or 2500 parts by weight to less than 3500 parts by weight, or 2800 parts by weight to less than 3300 parts by weight, or 2800 parts by weight to 3200 parts by weight, or 2900 parts by weight to It may be included in 3100 parts by weight, but is not limited thereto.
구체적으로, 상기 모노테르펜류는 팔마로사 오일 100 중량부를 기준으로, 10-4 중량부 초과 내지 200 중량부로 포함될 수 있고, 또는 10-3 중량부 내지 200 중량부, 또는 10-2 중량부 내지 200 중량부, 또는 10-1 중량부 내지 200 중량부, 또는 1 중량부 내지 200 중량부, 또는 10 중량부 내지 200 중량부, 또는 30 중량부 내지 200 중량부, 또는 50 중량부 내지 200 중량부, 또는 70 중량부 내지 200 중량부, 또는 90 중량부 내지 200 중량부, 또는 110 중량부 내지 200 중량부, 또는 110 중량부 내지 180 중량부, 또는 120 중량부 내지 180 중량부, 또는 120 중량부 내지 170 중량부, 또는 130 중량부 내지 180 중량부, 또는 130 중량부 내지 170 중량부, 또는 140 중량부 내지 160 중량부로 포함될 수 있으나, 이에 제한되는 것은 아니다.Specifically, the monoterpenes may be included in more than 10 -4 parts by weight to 200 parts by weight, or 10 -3 parts by weight to 200 parts by weight, or 10 -2 parts by weight to 200 parts by weight, based on 100 parts by weight of Palmarosa oil. part, or 10 -1 part by weight to 200 parts by weight, or 1 part by weight to 200 parts by weight, or 10 parts by weight to 200 parts by weight, or 30 parts by weight to 200 parts by weight, or 50 parts by weight to 200 parts by weight, or 70 parts by weight to 200 parts by weight, or 90 parts by weight to 200 parts by weight, or 110 parts by weight to 200 parts by weight, or 110 parts by weight to 180 parts by weight, or 120 parts by weight to 180 parts by weight, or 120 parts by weight to 170 parts by weight It may be included in parts by weight, or 130 parts by weight to 180 parts by weight, or 130 parts by weight to 170 parts by weight, or 140 parts by weight to 160 parts by weight, but is not limited thereto.
일 측면에서, 팔마로사 오일, 피록톤올아민, 숙신산 및 모노테르펜류를 상기와 같은 비율로 포함할 때, 가장 극대화된 두피 건강 또는 환경 개선 효과를 기대할 수 있다.In one aspect, when palmarosa oil, pyroctonolamine, succinic acid and monoterpenes are included in the above ratio, the most maximized scalp health or environmental improvement effect can be expected.
일 측면에서, 상기 모노테르펜류는, 테르피네올(terpineol), 유칼리프톨(eucalyptol), 오시멘(ocimene), 미르센(myrcene), 히노키티올(hinokitiol), 멘톨(menthol), 캠펜(camphene) 및 피넨(pinenes)으로 구성된 군으로부터 선택된 하나 이상을 포함할 수 있으나, 이에 제한되지 않는다.In one aspect, the monoterpenes are terpineol, eucalyptol, ocimene, myrcene, hinokitiol, menthol, camphene ) and pinenes, but may include one or more selected from the group consisting of, but is not limited thereto.
예컨대, 피부 감작성과 같이 인체 유해성이 없다면, 상기에 나열되지 않은 모노테르펜류도 본 발명의 조성물에 포함될 수 있다.For example, monoterpenes not listed above may also be included in the composition of the present invention if there is no harm to the human body such as skin sensitization.
일 측면에서, 상기 두피 건강 개선은 하기 중 하나 이상을 포함할 수 있다:In one aspect, improving scalp health can include one or more of the following:
i) 두피 악취 발생 억제 및 두피 악취 완화;i) inhibition of scalp odor generation and alleviation of scalp odor;
ii) 두피 피지 분비량 제어;ii) control of scalp sebum secretion;
iii) 두피 자극, 가려움 및 트러블 중 하나 이상의 완화; 및iii) relief of one or more of scalp irritation, itching and trouble; and
iv) 비듬균의 증식 억제 또는 비듬 생성 억제.iv) inhibiting the proliferation of dandruff bacteria or inhibiting dandruff production.
두피 악취 또는 정수리 악취는 스트레스에 의한 열, 두피 염증, 면역력 저하, 과도한 피지 분비와 축적된 노폐물 및 세균의 번식 등이 복합적으로 작용하면서 발생하는 것으로 알려져 있으며, 본 발명의 조성물은 두피 악취의 원인과 무관하게 우수한 악취 억제 효과를 나타낼 수 있다.It is known that scalp odor or parietal odor is caused by a combination of stress-induced heat, scalp inflammation, reduced immunity, excessive sebum secretion, accumulated waste products, and bacterial propagation. Regardless, it can exhibit excellent odor suppression effect.
비듬은, 두피의 각질이 떨어져 나온 것을 의미한다. 비듬은 일반적으로, 두피 상의 피지 양과 수분 함량의 밸런스 및 두피에 서식하는 세균총의 불균형으로 인해 발생한다. 비듬을 유발하는 주요 세균으로는 말라세지아 퍼퍼(Malassezia furfur)가 알려져 있으며 최근에는 말라세지아 퍼퍼 외에도 프로피오니박테리움(Propionibacterium)속 세균과 스테필로코커스(Staphylococcus)속 세균이 지목되고 있다.Dandruff means that dead skin cells on the scalp have come off. Dandruff is generally caused by an imbalance between the amount of sebum and water content on the scalp and the flora inhabiting the scalp. Malassezia furfur is known as the main bacterium causing dandruff, and recently, bacteria of the genus Propionibacterium and bacteria of the genus Staphylococcus have been pointed out in addition to Malassezia furfur.
피지는 피지선에서 분비되는 반유동 오일성 물질로, 주요 성분은 콜레스테롤, 지방산 및 에스테르 화합물 등이다. 피지는 피부와 모발 표면에 지방막을 형성하여 보습 기능을 하고, 피지에 함유된 비타민 D 전구체는 자외선을 받아 비타민 D로 전환된 후 두피로 다시 흡수되어 인체 면역 세포 생산에 관여하는 것으로 알려져 있다.Sebum is a semi-liquid oily substance secreted by the sebaceous glands, and its main components are cholesterol, fatty acids and ester compounds. It is known that sebum forms a fat film on the surface of the skin and hair to provide a moisturizing function, and the vitamin D precursor contained in sebum is converted to vitamin D by receiving ultraviolet rays and then absorbed back into the scalp to be involved in the production of human immune cells.
피지 분비량은 두피 건강에 직접적인 영향을 미치는데, 피지가 적정량보다 소량 분비될 경우에는 두피와 모발에서의 수분 증발량이 증가하여 건조한 환경이 조성된다. 또한, 피지가 과다 분비될 경우에는 비듬 유발균들의 증식이 활발해지면서 염증반응이 일어나고, 피지비듬 유발균의 대사산물노폐물 등이 모공을 막아 피부염을 일으키고, 두피 자극감 및 트러블을 유발한다.The amount of sebum secretion has a direct effect on the health of the scalp. When a smaller amount of sebum is secreted than an appropriate amount, the amount of moisture evaporation from the scalp and hair increases, creating a dry environment. In addition, when sebum is secreted excessively, dandruff-inducing bacteria proliferate actively, causing an inflammatory reaction, and metabolite waste products of sebum-dandruff-inducing bacteria clog pores, causing dermatitis, and causing scalp irritation and trouble.
일 측면에서, 상기 조성물은 화장료 조성물 또는 약학적 조성물일 수 있다.In one aspect, the composition may be a cosmetic composition or a pharmaceutical composition.
일 측면에서, 상기 조성물의 투여경로는 제한되지 않으나, 바람직하게는 경피 또는 피부 외용일 수 있다.In one aspect, the route of administration of the composition is not limited, but may be preferably transdermal or external skin.
일 측면에서, 상기 화장료 조성물은, 예를 들어, 염모제, 샴푸, 린스, 세럼, 트리트먼트, 헤어팩, 앰플, 헤어크림, 정발제, 양모제, 연고, 헤어젤, 헤어패치, 미스트, 헤어스타일링제, 비누 등 두피 및/또는 모발에 사용하는 조성물을 포함하며, 상기 예시에 한정되지는 않는다.In one aspect, the cosmetic composition, for example, hair dye, shampoo, rinse, serum, treatment, hair pack, ampoule, hair cream, hair styling agent, hair conditioner, ointment, hair gel, hair patch, mist, hair styling agent, It includes a composition used for scalp and/or hair, such as soap, but is not limited to the above examples.
상기 화장료 조성물은 국소 적용에 적합한 모든 제형으로 제공될 수 있다. 예를 들면, 용액, 에멀젼(W/O, O/W, W/O/W 등), 현탁액, 고체, 겔, 분말, 페이스트, 마이크로 니들, 포말(foam) 또는 에어로졸 조성물의 제형으로 제공될 수 있다. 이러한 제형의 조성물은 당해 분야의 통상적인 방법에 따라 제조될 수 있다. The cosmetic composition may be provided in any formulation suitable for topical application. For example, it may be provided in the form of a solution, emulsion (W/O, O/W, W/O/W, etc.), suspension, solid, gel, powder, paste, microneedle, foam or aerosol composition. there is. Compositions of such formulations may be prepared according to conventional methods in the art.
본 발명의 일 관점에 의한 약학 조성물은 비경구 투여제로 제제화할 수 있다.The pharmaceutical composition according to one aspect of the present invention may be formulated for parenteral administration.
비경구 투여를 위한 제제는 주사제, 점적제, 연고, 로션, 스프레이, 현탁제, 유제 또는 좌제 (坐劑) 등을 들 수 있다. 본 발명의 일측면에 따른 조성물은 계면 활성제, 부형제, 착색료, 향신료, 보존료, 안정제, 완충제, 현탁제 또는 기타 상용하는 보조제를 적절히 사용할 수 있다. Formulations for parenteral administration include injections, drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and the like. The composition according to one aspect of the present invention may appropriately use surfactants, excipients, coloring agents, spices, preservatives, stabilizers, buffers, suspending agents, or other commonly used adjuvants.
본 발명의 일측면에 따른 조성물에 포함된 유효 성분은 담체와 함께 혼합되거나, 용기 형태의 담체 내에 봉입되어 제공될 수 있다. 희석제가 담체로 사용되는 경우 희석제는 유효 성분에 대해 담체, 부형제 또는 매질(medium)로 작용할 수 있는 고형, 반고형 또는 액상의 물질일 수 있다. 적절한 담체, 부형제 또는 희석제의 예로는, 락토오스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐피롤리돈, 물, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 또는 광물유를 들 수 있다. 본 발명의 다른 일측면에서, 조성물은 충진제, 항응집제, 윤활제, 습윤제, 향료, 유화제 또는 방부제 등을 추가로 포함할 수 있다.The active ingredient included in the composition according to one aspect of the present invention may be provided by being mixed with a carrier or encapsulated in a carrier in the form of a container. When a diluent is used as a carrier, the diluent may be a solid, semi-solid or liquid substance that can act as a carrier, excipient or medium for the active ingredient. Examples of suitable carriers, excipients or diluents are lactose, dextrose, sucrose, sorbitol, mannitol, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydro hydroxybenzoate, talc, magnesium stearate or mineral oil. In another aspect of the present invention, the composition may further include a filler, an anti-agglomerating agent, a lubricant, a wetting agent, a flavoring agent, an emulsifier or a preservative.
일 측면에서, 본 발명의 화장료 조성물 및/또는 약학적 조성물은, 팔마로사 오일, 피록톤올아민, 숙신산 및 모노테르펜류를 각각 조성물 총 중량을 기준으로, 0.05 내지 5.0 중량 %로 포함할 수 있다.In one aspect, the cosmetic composition and/or pharmaceutical composition of the present invention may include palmarosa oil, pyroctonolamine, succinic acid, and monoterpenes in an amount of 0.05 to 5.0% by weight, based on the total weight of the composition.
구체적으로, 팔마로사 오일, 피록톤올아민, 숙신산 및 모노테르펜류는 각각 조성물 총 중량을 기준으로, 0.05 내지 4.5 중량%, 또는 0.1 내지 4.5 중량%, 0.1 내지 4.0 중량%, 또는 0.1 내지 3.5 중량%, 또는 0.1 내지 2.5 중량%, 또는 0.3 내지 2.5 중량%, 또는 0.5 내지 2.5 중량%, 또는 0.5 내지 2.0 중량%, 또는 0.5 내지 1.7 중량%, 또는 0.7 내지 1.7 중량%, 또는 0.7 내지 1.5 중량%, 또는 0.7 내지 1.3 중량%, 또는 0.8 내지 1.2 중량%로 포함될 수 있으나, 이에 제한되는 것은 아니다.Specifically, palmarosa oil, pyroctoneolamine, succinic acid, and monoterpenes are each from 0.05 to 4.5% by weight, or 0.1 to 4.5% by weight, 0.1 to 4.0% by weight, or 0.1 to 3.5% by weight, based on the total weight of the composition, or 0.1 to 2.5%, or 0.3 to 2.5%, or 0.5 to 2.5%, or 0.5 to 2.0%, or 0.5 to 1.7%, or 0.7 to 1.7%, or 0.7 to 1.5%, or It may be included in 0.7 to 1.3% by weight, or 0.8 to 1.2% by weight, but is not limited thereto.
본 명세서에 따른 화장료 조성물 및 약학적 조성물에는 본 명세서의 성분들 이외에 기능성 첨가물 및 일반적인 화장료 조성물에 포함되는 성분이 추가로 포함될 수 있다. 상기 기능성 첨가물로는 예컨대, 비타민, 펩티드, 다당류, 기타 식물 추출물 등을 예시로 들 수 있다. 상기 화장료 조성물 및/또는 약학적 조성물은 주된 효과를 손상시키지 않는 범위 내에서, 바람직하게는 주된 효과에 상승 효과를 줄 수 있는 다른 성분들을 포함할 수 있다.The cosmetic composition and pharmaceutical composition according to the present specification may further include functional additives and components included in general cosmetic compositions in addition to the components of the present specification. Examples of the functional additive include, for example, vitamins, peptides, polysaccharides, and other plant extracts. The cosmetic composition and / or pharmaceutical composition may include other components that can give a synergistic effect to the main effect within a range that does not impair the main effect.
이하 제조예 및 실험예를 통하여 본 발명에 대해 구체적으로 설명하기로 한다. 이들 예는 단지 본 발명을 예시하기 위한 것이므로, 본 발명의 범위가 이들 예에 의해 제한되는 것은 아니다.Hereinafter, the present invention will be described in detail through preparation examples and experimental examples. These examples are only for exemplifying the present invention, and the scope of the present invention is not limited by these examples.
[제조예] [Production Example]
하기 표 1에 기재된 성분 및 비율을 이용하여 통상적인 방법에 따라 혼합하여 조성물 (실시예 1 내지 5, 비교예 1 내지 6)을 제조하였다. Compositions (Examples 1 to 5, Comparative Examples 1 to 6) were prepared by mixing according to a conventional method using the components and ratios shown in Table 1 below.
※ 단위: 중량비※ Unit: weight ratio
한편, 비교예 4, 5는 과량으로 포함한 피록톤올아민, 석시닉 애씨드가 석출되는 현상으로 안정성이 좋지 않았으며, 비교예 6은 과량의 4-터피네올 함유로 인해 강한 향취의 문제점과 과도한 오일감으로 자극감이 느껴졌다. On the other hand, Comparative Examples 4 and 5 had poor stability due to precipitation of pyroctoneolamine and succinic acid, which contained excessive amounts of 4-terpineol. I felt a sense of stimulation.
[실험예] [Experimental example]
[실험예 1], 두피 자극, 가려움, 트러블, 비듬 완화[Experimental Example 1], scalp stimulation, itching, trouble, dandruff relief
20~30대 남성 및 여성 각각 10 명, 10명에게 두피에 사용하여 두피 개선(자극, 가려움, 트러블, 비듬 완화) 의 종합 평가에 대한 만족도 조사를 실시하였으며, 그 결과를 표 2에 나타 내었다. 상기 표 1 실시예 1 내지 5 및 비교예 1 내지 3의 조성물을 1.0% 적용한 헤어 토닉 샘플을 2주간 사용하도록 한 후, 평가 항목에 느낌을 평가 척도로서 5단계로 평가하고, 점수는 5점 만점으로 단계에 따라 1점 단위로 부여하였다.A satisfaction survey was conducted on the comprehensive evaluation of scalp improvement (irritation, itching, trouble, dandruff relief) by using it on the scalp for 10 men and 10 women in their 20s and 30s, respectively, and the results are shown in Table 2. After using the hair tonic samples to which 1.0% of the compositions of Examples 1 to 5 and Comparative Examples 1 to 3 in Table 1 were applied for 2 weeks, the feeling was evaluated in 5 stages as an evaluation scale, and the score was 5 out of 5. was assigned in units of 1 point according to the stage.
상기 표 2에서와 같이 본 발명에 의한 실시예 1 내지 5 는 두피 자극, 가려움, 트러블, 비듬 완화의 종합적 개선도에서 모두 비교예 1~3에 비해 높은 평가를 받았음을 확인할 수 있었다. As shown in Table 2, it was confirmed that Examples 1 to 5 according to the present invention received higher evaluations than Comparative Examples 1 to 3 in terms of overall improvement in scalp irritation, itching, trouble, and dandruff relief.
[실험예 2] Malassezia furfur KCTC 7545에 대한 항균 활성 테스트[Experimental Example 2] Antibacterial activity test for Malassezia furfur KCTC 7545
본 실험에 사용된 균주는 Malassezia furfur (KCTC No.7545)이며, 이를 single colony 분리하여 30℃(도씨)에서 48시간 배양 후 OD값을 측정하였다. 그 후 균주와 시료(실시예 및 비교예)를 각각 혼합하여 고농도부터 8구간 2 fold (50%~0.39%) 희석하여, 30℃에서 48시간 배양 진행하였다. 흡광도는 Micro plate reader 장비를 사용하여 측정(600nm)하였고, 편차 신뢰도를 위해 실험을 2회 반복 진행하여 비교값을 확인하였다. 시료별로 초기 흡광도 대비 48시간 이후에도 흡광도가 증가하지 않은 구간의 MIC 농도를 확인하였다. M. furfur의 성장율에 대한 결과값은 아래 표 3에 기재된 바와 같다. The strain used in this experiment was Malassezia furfur (KCTC No.7545), which was single-colonized and cultured for 48 hours at 30 ° C (degree Celsius), and then the OD value was measured. After that, the strain and the sample (Examples and Comparative Examples) were mixed, diluted 2 fold (50% to 0.39%) in 8 sections from high concentration, and cultured at 30 ° C. for 48 hours. The absorbance was measured (600 nm) using a micro plate reader equipment, and the comparison value was confirmed by repeating the experiment twice for deviation reliability. The MIC concentration in the section where the absorbance did not increase even after 48 hours compared to the initial absorbance for each sample was confirmed. The results for the growth rate of M. furfur are shown in Table 3 below.
상기 표 3에서와 같이 본 발명의 실시예 1,2,3,4,5는 비듬균에 대한 항균활성이 비교예 1 내지 3에 비해 현저히 우수한 것을 확인할 수 있었다.As shown in Table 3, it was confirmed that Examples 1, 2, 3, 4, and 5 of the present invention had significantly better antibacterial activity against dandruff bacteria than Comparative Examples 1 to 3.
[실험예 3] 두피 소취 평가 [Experimental Example 3] Scalp deodorization evaluation
두피 냄새 제거를 확인하기 위하여 20~30세의 시험 부위에 피부 질환이 없는 사람으로 선정하였으며, 20명을 대상으로 상기 실시예 1 내지 5 및 비교예 1 내지 3를 각각 0.1% 적용한 헤어 토닉을 1일 1회로 2주 동안 실시하고, 소취 효과 만족도를 하기 평가 기준에 따라 평가하여 평균한 결과를 하기 표 4에 나타내었다.In order to confirm the removal of scalp odor, people aged 20 to 30 years without skin disease were selected, and 20 people were selected as hair tonics to which 0.1% of each of Examples 1 to 5 and Comparative Examples 1 to 3 was applied to 20 people. It was performed once a day for 2 weeks, and the deodorizing effect satisfaction was evaluated according to the following evaluation criteria, and the average results are shown in Table 4 below.
[※ 소취 평가 기준 : 1: 매우 불량이다, 2: 불량이다, 3: 보통이다, 4: 우수하다, 5: 매우 우수하다][※ Deodorization evaluation criteria: 1: very poor, 2: poor, 3: average, 4: excellent, 5: very good]
상기 표 4에서 확인할 수 있듯이 본 발명에 따른 실시예 1~5의 포함하는 화장료 조성물은 비교예 1~3에 비해 소취효과가 우수함을 확인할 수 있었다.As can be seen in Table 4, it was confirmed that the cosmetic compositions containing Examples 1 to 5 according to the present invention have excellent deodorizing effects compared to Comparative Examples 1 to 3.
[실험예 4] 두피 환경 개선 평가[Experimental Example 4] Scalp environment improvement evaluation
하기 표의 제형예 1을 만 20~59세의 여성 32명을 대상으로 1회 사용 후 두피 각질, 두피 유분 및 두피 보습을 측정하였고, 2주간 사용하여 두피 붉은기(진정) 및 두피 혈행 개선, 두피 가려움 완화에 대한 인체 효능 평가를 실시하여 다음과 같은 결과를 확인하였다. After using Formulation Example 1 in the following table once for 32 women aged 20 to 59 years old, scalp keratin, scalp oil, and scalp moisture were measured, and scalp redness (sedation) and scalp blood circulation improved, scalp after 2 weeks of use Human efficacy evaluation for itch relief was conducted to confirm the following results.
1. 측정 기기1. Measuring instruments
- 두피 각질 측정: D-squame, Visioscan VC98 - Scalp keratin measurement: D-squame, Visioscan VC98
- 두피 유분 측정: Sebumeter SM815 - Scalp oil measurement: Sebumeter SM815
- 두피 보습 측정: DemaLab Hydration pin probe - Scalp moisture measurement: DemaLab Hydration pin probe
- 두피 가려움 완화 측정: Tewameter TM Nano, 시험대상자 VAS 평가 - Scalp itching relief measurement: Tewameter TM Nano, subject VAS evaluation
- 두피 붉은기(진정) 측정: ASW300, I-Max Plus - Scalp redness (sedation) measurement: ASW300, I-Max Plus
- 두피 혈행 측정: Laser doppler PIM3 - Scalp blood circulation measurement: Laser doppler PIM3
2. 측정 결과2. Measurement results
(1) 두피 각질 측정 (D.I., %) (1) Scalp keratin measurement (D.I., %)
시험제품(제형예 1) 사용 후 두피 각질 측정값은, 사용 전에 비해 사용 직후 유의한 수준(p<0.05)으로 감소하여, 두피 각질이 개선됨을 확인하였다. After using the test product (Formulation Example 1), the scalp keratin measurement value decreased to a significant level (p<0.05) immediately after use compared to before use, confirming that scalp keratin was improved.
(2) 두피 유분 측정 (μg/cm2)(2) Measurement of scalp oil (μg/cm 2 )
시험제품 사용 후 두피 유분 측정값은, 사용 전에 비해 사용 직후 유의한 수준(p<0.05)으로 감소하여, 두피 유분이 개선됨을 확인하였다. After using the test product, the scalp oil measurement value decreased to a significant level (p<0.05) immediately after use compared to before use, confirming that scalp oil was improved.
(3) 두피 보습 측정 (μS)(3) Measurement of scalp moisture (μS)
시험제품 사용 후 두피 보습 측정값은, 사용 전에 비해 사용 직후 유의한 수준(p<0.05)으로 증가하여, 두피 보습이 개선됨을 확인하였다. After using the test product, the scalp moisturizing measurement value increased to a significant level (p <0.05) immediately after use compared to before use, confirming that scalp moisturizing was improved.
(4) 두피 가려움 완화 측정 (4) Scalp itching relief measurement
(4-1) 수분손실량 측정(g/m2h) (4-1) Measurement of water loss (g/m 2 h)
시험제품 사용 후 두피 수분 손실량 측정값은, 사용 전에 비해 사용 2주 후 유의한 수준(p<0.05)으로 감소하여, 두피 수분 손실량이 개선됨을 확인하였다. After using the test product, the measured value of scalp moisture loss decreased to a significant level (p<0.05) after 2 weeks of use compared to before use, confirming that scalp moisture loss was improved.
(4-2) 가려움증 개선도 평가(VAS) (4-2) Itch improvement evaluation (VAS)
시험제품 사용 후 가려움증 개선도 평가(VAS) 점수는, 제품 사용 전에 비해 제품 사용 2주 후 모두 유의한 수준 (p<0.05)으로 감소하여 개선됨을 확인하였다. It was confirmed that the itching improvement evaluation (VAS) score after using the test product decreased to a significant level (p<0.05) after 2 weeks of product use compared to before product use.
(5) 두피 붉은기(진정) 측정 (a-value)(5) Scalp redness (sedation) measurement (a-value)
시험 제품 사용 2주 후 두피 붉은기(진정) 측정값은, 사용 용 전에 비해 사용 2주 후 유의한 수준(p<0.05)으로 감소하여 개선됨을 확인하였다. After 2 weeks of using the test product, the measured value of scalp redness (sedation) decreased to a significant level (p<0.05) after 2 weeks of use compared to before use, confirming that it was improved.
(6) 두피혈행측정(P.U) - 시험제품 사용 2주 후 두피 혈행 측정값은, 사용 전에 비해 사용 2주 후 유의한 수준(p<0.05)으로 증가하여 개선됨을 확인하였다. (6) Scalp blood circulation measurement (P.U) - After 2 weeks of using the test product, the scalp blood circulation measurement value increased at a significant level (p<0.05) after 2 weeks of use compared to before use, confirming that it was improved.
[제형예 1] 제조예의 조성물을 포함하는 샴푸의 제조 [Formulation Example 1] Preparation of shampoo containing the composition of Preparation Example
본 발명에 따른 조성물을 활용하여, 샴푸를 제조하였다. 샴푸는 아래 표 5의 배합에 따라 통상적인 방법으로 제조하였다.Utilizing the composition according to the present invention, a shampoo was prepared. Shampoo was prepared in a conventional manner according to the formulations in Table 5 below.
Claims (7)
상기 조성물은,
i) 팔마로사 오일(Palmarosa oil); ii) 피록톤올아민(Piroctone Olamine); 및 iii) 숙신산(Succinic acid) 및 모노테르펜류(Monoterpenes) 중 하나 이상을 유효성분으로 포함하며,
상기 피록톤올아민은, 팔마로사 오일 100 중량부 대비 10-2 중량부 내지 150 중량부로 포함되고,
상기 숙신산은, 팔마로사 오일 100 중량부 대비 10-4 중량부 초과 내지 3500 중량부 미만으로 포함되며,
상기 모노테르펜류는, 팔마로사 오일 100 중량부 대비 10-4 중량부 초과 내지 200 중량부로 포함되는 두피 건강 개선용 조성물.
As a composition for improving scalp health,
The composition,
i) Palmarosa oil; ii) Piroctone Olamine; and iii) at least one of succinic acid and monoterpenes as an active ingredient,
The pyroctoneolamine is included in 10 -2 parts by weight to 150 parts by weight based on 100 parts by weight of Palmarosa oil,
The succinic acid is included in an amount greater than 10 -4 parts by weight and less than 3500 parts by weight based on 100 parts by weight of Palmarosa oil,
The monoterpenes, palmarosa oil 100 parts by weight compared to 10 -4 parts by weight of more than 200 parts by weight of scalp health improving composition.
상기 모노테르펜류는 테르피네올(terpineol), 유칼리프톨(eucalyptol), 오시멘(ocimene), 미르센(myrcene), 히노키티올(hinokitiol), 멘톨(menthol), 캠펜(camphene) 및 피넨(pinenes)으로 구성된 군으로부터 선택된 하나 이상을 포함하는, 두피 건강 개선용 조성물.
According to claim 1,
The monoterpenes include terpineol, eucalyptol, ocimene, myrcene, hinokitiol, menthol, camphene, and pinene. ) Containing at least one selected from the group consisting of, a composition for improving scalp health.
상기 두피 건강 개선은 하기 중 하나 이상을 포함하는, 두피 건강 개선용 조성물:
i) 두피 악취 발생 억제 및 두피 악취 완화;
ii) 두피 피지 분비량 제어;
iii) 두피 자극, 가려움 및 트러블 중 하나 이상의 완화; 및
iv) 비듬균의 증식 억제 또는 비듬 생성 억제.
According to claim 1,
The scalp health improvement composition for improving scalp health, comprising one or more of the following:
i) inhibition of scalp odor generation and alleviation of scalp odor;
ii) control of scalp sebum secretion;
iii) relief of one or more of scalp irritation, itching and trouble; and
iv) inhibiting the proliferation of dandruff bacteria or inhibiting dandruff production.
상기 조성물은, 화장료 조성물 또는 약학적 조성물이며,
상기 약학적 조성물은 두피 가려움증 완화용인, 두피 건강 개선용 조성물.
According to claim 1,
The composition is a cosmetic composition or a pharmaceutical composition,
The pharmaceutical composition is for alleviating itching of the scalp, a composition for improving scalp health.
상기 화장료 조성물 또는 약학적 조성물은,
팔마로사 오일, 피록톤올아민, 숙신산 및 모노테르펜류를 각각 조성물 총 중량을 기준으로, 0.05 내지 5.0 중량 %로 포함하는, 두피 건강 개선용 조성물. According to claim 6,
The cosmetic composition or pharmaceutical composition,
A composition for improving scalp health comprising palmarosa oil, pyroctonolamine, succinic acid and monoterpenes in an amount of 0.05 to 5.0% by weight, based on the total weight of the composition, respectively.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220066770A KR102513124B1 (en) | 2022-05-31 | 2022-05-31 | Composition for improving environment of scalp, relieving odor of scalp and suppressing danddruff |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220066770A KR102513124B1 (en) | 2022-05-31 | 2022-05-31 | Composition for improving environment of scalp, relieving odor of scalp and suppressing danddruff |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102513124B1 true KR102513124B1 (en) | 2023-03-23 |
Family
ID=85799224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220066770A KR102513124B1 (en) | 2022-05-31 | 2022-05-31 | Composition for improving environment of scalp, relieving odor of scalp and suppressing danddruff |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102513124B1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100521783B1 (en) * | 2002-07-23 | 2005-10-14 | 주식회사 내츄로바이오텍 | Composition containing extract derived from natural products that have growth-inhibition activity against dandruff causing microorganism |
KR100719479B1 (en) * | 2000-09-01 | 2007-05-17 | 주식회사 엘지생활건강 | Anti-dandruff hair composition |
KR101503922B1 (en) * | 2008-03-07 | 2015-03-18 | 주식회사 엘지생활건강 | Hair care compositions comprising an extract of black cereals |
KR102323101B1 (en) | 2014-12-31 | 2021-11-10 | (주)아모레퍼시픽 | Composition for improving hair and scalp condition coprising extract of hydrangea serrata |
-
2022
- 2022-05-31 KR KR1020220066770A patent/KR102513124B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100719479B1 (en) * | 2000-09-01 | 2007-05-17 | 주식회사 엘지생활건강 | Anti-dandruff hair composition |
KR100521783B1 (en) * | 2002-07-23 | 2005-10-14 | 주식회사 내츄로바이오텍 | Composition containing extract derived from natural products that have growth-inhibition activity against dandruff causing microorganism |
KR101503922B1 (en) * | 2008-03-07 | 2015-03-18 | 주식회사 엘지생활건강 | Hair care compositions comprising an extract of black cereals |
KR102323101B1 (en) | 2014-12-31 | 2021-11-10 | (주)아모레퍼시픽 | Composition for improving hair and scalp condition coprising extract of hydrangea serrata |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8394395B2 (en) | Use of a cosmetic composition for the care of fatty skin | |
JPH09295921A (en) | Hair growing and tonic agent | |
KR102369387B1 (en) | Cosmetic Composition for prevention of depilation or improvement of hair growth | |
KR100564386B1 (en) | A pharmaceutical composition for the treatment of seborrhea containing 4-hydroxy-5-methoxy-4-[2-methyl-3-3-methyl-2-butenyl-2-oxiranyl]-1-oxaspiro[2,5]octan-6-one | |
JPH07126146A (en) | Sin external preparation | |
JP3590369B2 (en) | Cosmetic composition for preventing and treating acne containing cryptotanshinone | |
KR102513124B1 (en) | Composition for improving environment of scalp, relieving odor of scalp and suppressing danddruff | |
WO2016033899A1 (en) | Dandruff removing composition for adjusting scalp oil balance | |
JPH03112912A (en) | Cosmetic composition | |
KR20210083236A (en) | Composition for preventing hair loss and improving the scalp | |
JP4492918B2 (en) | Antibacterial agent and antibacterial product using the same | |
KR102429344B1 (en) | A cosmetic composition for anti-dandruff comprising extract of Polygala tenuifolia or Lycium chinense | |
KR102428010B1 (en) | Skin external composition | |
KR102504560B1 (en) | Skin external composition | |
KR102435397B1 (en) | Skin external composition | |
JP2004323476A (en) | Antimycotic agent and antimicrobial product produced by using the same | |
JP2023092422A (en) | hair care composition | |
KR102048708B1 (en) | Composition for Anti-dandruff | |
KR100858196B1 (en) | Dermal composition containning active ingradient extracted from Myristicae semen | |
KR102049116B1 (en) | Composition for Anti-Malassezia | |
JP2021172604A (en) | Skin condition improver | |
KR20220034272A (en) | Composition for preventing hair loss or promoting hair growth | |
CN114423411A (en) | Use of olive kernel extract in cosmetics or health products | |
KR20210070777A (en) | Composition for skin barrier | |
KR20220082832A (en) | Novel cosmetic use of N-methylglycine to increase the diversity of skin microflora |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AMND | Amendment | ||
X091 | Application refused [patent] | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |